Nykode Therapeutics ASA — Board/Management Information 2021

May 5, 2021

Vaccibody AS appoints Dr. Volck, M.D., Ph.D. as new member of the Board

Vaccibody AS appoints Dr. Volck, M.D., Ph.D. as new member of the Board

Oslo, Norway, May 05, 2021 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced the appointment of Dr. Volck, M.D., Ph.D. to its Board of Directors.

“I am excited to welcome Dr. Birgitte Volck to our Board. Dr. Volck is a seasoned R&D executive with broad international experience. Her valuable expertise will help guide and support Vaccibody in this transformational period of expansion and clinical pipeline acceleration.” said Anders Tuv, Chairperson of Vaccibody AS.

Dr. Volck has over 20 years of leadership experience in the biotechnology and pharmaceutical industry.

Dr. Volck has served as the President R&D at AVROBIO Inc. (Nasdaq), a clinical stage gene therapy company. Prior to this, she served as head of Research and Development, Rare Diseases, for GlaxoSmithKline. Before that, Dr. Volck was the Chief Medical Officer and Senior Vice President of Development at Swedish Orphan Biovitrum AB. She has held various positions at Amgen Inc., including Executive Development Director, Bone, Neuroscience & Inflammation and served as Nordic Medical Director and Project Director at Genzyme A/S. She currently serves as Director of Ascendis Pharma A/S (Nasdaq) and Soleno Therapeutics Inc. (Nasdaq). Dr. Volck received her M.D. and Ph.D. degrees from Copenhagen University, Denmark.

About Vaccibody

Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies. The Company develops vaccines for the treatment cancer and infectious diseases. Vaccibody’s vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen-specific immune responses and elicit efficacious clinical responses. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer; and VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer and cancer of the head & neck. Further, the Company has collaborations with Roche and Nektar Therapeutics within oncology.

Additionally, Vaccibody intends to leverage the potential of its platform in infectious disease indications, including its second-generation COVID-19 vaccine program, VB10.COV2.

Vaccibody’s shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information about Vaccibody may be found at http://www.vaccibody.com

Contact for Vaccibody:

CEO Michael Engsig

Vaccibody AS

Cell: +45 6173 1509

mengsig@vaccibody.com

Vaccibody AS

Oslo Science Park

Gaustadalléen 21

0349 Oslo, Norway

Forward-looking statements for Vaccibody

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.